Seddon P A, Hrinya M K, Gaynord M A, Lion C M, Mangold B M, Bruns F J
Renal Electrolyte Division, University of Pittsburgh Medical Center, Pennsylvania 15213, USA.
ASAIO J. 1998 Sep-Oct;44(5):M559-61. doi: 10.1097/00002480-199809000-00049.
Thrombosis, a major cause of hemodialysis catheter dysfunction, can be treated with urokinase. We compared protocols using full strength urokinase to the volume of the catheter with low dose therapy. Clotting episodes and successful declottings (blood flow > 200 ml/min) were tracked for 6 months. One hundred four clotting episodes were treated with 5,000 U/ml urokinase to the volume of the catheter lumen for a 1 hr dwell. If unsuccessful, a second dose of 5,000 U/ml was administered and, if needed, a third dose of 125,000 U/lumen. Post treatment, catheters were locked with 5,000 U/ml heparin to the volume of the lumen. Using new protocols, clotting episodes were treated with 2,500 U/lumen urokinase, followed by saline to the volume of the lumen for a 1 hr dwell. A mid dwell injection of 0.2 ml/lumen saline was added to advance the front of active urokinase. If unsuccessful, a second 2,500 U/lumen dose was administered. Heparin lock was 10,000 U/ml heparin to the volume of the lumen. Revised protocols decreased clotting episodes 60% and urokinase charges 81%, while maintaining successful declottings at 74%. Low dose urokinase was as effective as full strength when the active front was advanced mid dwell.
血栓形成是血液透析导管功能障碍的主要原因,可用尿激酶治疗。我们将使用全强度尿激酶与导管容积的方案与低剂量疗法进行了比较。对凝血事件和成功的解凝(血流量>200 ml/分钟)进行了6个月的跟踪。104次凝血事件采用5000 U/ml尿激酶注入导管内腔容积并保留1小时进行治疗。如果不成功,则给予第二剂5000 U/ml,如果需要,给予第三剂125000 U/内腔。治疗后,导管用5000 U/ml肝素封管至内腔容积。采用新方案时,凝血事件用2500 U/内腔尿激酶治疗,然后注入生理盐水至内腔容积并保留1小时。在保留期间注入0.2 ml/内腔的生理盐水以推进活性尿激酶前沿。如果不成功,则给予第二剂2500 U/内腔。肝素封管液为10000 U/ml肝素至内腔容积。修订后的方案使凝血事件减少了60%,尿激酶费用减少了81%,同时成功解凝率保持在74%。当活性前沿在保留期间推进时,低剂量尿激酶与全强度尿激酶效果相同。